19.59
전일 마감가:
$20.09
열려 있는:
$20.12
하루 거래량:
2.93M
Relative Volume:
1.23
시가총액:
$2.46B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-9.6502
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
+0.62%
1개월 성능:
+6.53%
6개월 성능:
-34.70%
1년 성능:
-49.61%
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
APLS
Apellis Pharmaceuticals Inc
|
19.59 | 2.52B | 715.22M | -250.10M | -205.58M | -2.03 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
아펠리스 Stock (APLS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-10-16 | 개시 | William Blair | Outperform |
2024-05-31 | 개시 | Piper Sandler | Neutral |
2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2023-11-09 | 개시 | Goldman | Buy |
2023-11-02 | 개시 | Mizuho | Neutral |
2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-08-29 | 재확인 | Citigroup | Buy |
2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
2022-07-19 | 개시 | H.C. Wainwright | Buy |
2022-06-17 | 재개 | Stifel | Buy |
2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
2021-12-08 | 개시 | Wells Fargo | Overweight |
2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
2021-09-10 | 재확인 | Credit Suisse | Neutral |
2021-09-10 | 재확인 | Needham | Buy |
2021-09-10 | 재확인 | Oppenheimer | Outperform |
2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
2021-08-19 | 개시 | Jefferies | Buy |
2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
2021-05-21 | 개시 | UBS | Buy |
2021-04-16 | 개시 | Goldman | Buy |
2020-11-19 | 개시 | Needham | Buy |
2020-09-01 | 개시 | Stifel | Buy |
2020-07-20 | 개시 | ROTH Capital | Buy |
2020-06-17 | 개시 | BTIG Research | Neutral |
2020-04-01 | 개시 | Raymond James | Strong Buy |
2020-03-31 | 개시 | BMO Capital Markets | Outperform |
2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
2019-12-19 | 개시 | BofA/Merrill | Buy |
2019-11-22 | 개시 | Wedbush | Underperform |
2019-11-05 | 개시 | Credit Suisse | Neutral |
2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-03-29 | 개시 | Robert W. Baird | Outperform |
2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Is Apellis Pharmaceuticals Inc. a good long term investmentOver 200% growth - PrintWeekIndia
What analysts say about Apellis Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025 - GuruFocus
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - The Manila Times
Fierce Biotech Layoff Tracker 2025: Rocket ejects 30% of staffers; Flagship's Tessera and Generate Bio trim teams - Fierce Biotech
Complement 3 Glomerulopathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com
Apellis Pharmaceuticals Inc. Stock Analysis and ForecastOutstanding trading profits - jammulinksnews.com
What drives Apellis Pharmaceuticals Inc. stock priceExceptional market performance - jammulinksnews.com
Intermediate Age-Related Macular Degeneration Market Research 2025-2035 Featuring Novartis, Allegro Ophthalmics, and Apellis PharmaceuticalsResearchAndMarkets.com - FinancialContent
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Raises Target Price to $50 - 富途牛牛
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
APLS Stock Update: B of A Securities Raises Price Target | APLS - GuruFocus
Apellis price target raised to $24 from $23 at BofA - TipRanks
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - The Manila Times
Apellis Reveals 48-Month SYFOVRE Data: 5 Key Studies Show Promise for Geographic Atrophy Treatment - Stock Titan
H.C. Wainwright reiterates Buy rating on Apellis Pharmaceuticals stock By Investing.com - Investing.com Canada
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals (APLS) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Apellis stock holds Outperform rating at William Blair amid Izervay competition - Investing.com Canada
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Cantor Fitzgerald reiterates Apellis stock Overweight rating with $39 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL) - The Globe and Mail
16 Most Promising Stocks According to Wall Street Analysts - Insider Monkey
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating - MSN
Morgan Stanley raised the Target Price of Apellis Pharmaceuticals (APLS.US) to $26 and maintained a "Hold" rating. - 富途牛牛
Apellis stock surges after Sobi $300 million royalty deal - MSN
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing - MSN
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
WilmerHale Advises Apellis Pharmaceuticals in Purchase Agreement with Sobi - WilmerHale
(APLS) Trading Advice - news.stocktradersdaily.com
Apellis signs royalty purchase deal with Sobi for Aspaveli - MSN
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli - MSN
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Apellis Pharmaceuticals (APLS) and Pliant Therapeutics (PLRX) - The Globe and Mail
What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):